Ghent (Belgium), 10 May 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, is poised for exponential growth in 2024.

Introduction

The bonyf achievement of compliance with the stringent European Medical Device Regulation (MDR) has significantly bolstered our market position and enhanced our credibility as a reliable and sustainable manufacturer.

Leveraging our compliance status and unique product offerings, nurture our new business model implemented since end 2022 whereas bonyf establishes itself a significant global player in contract manufacturing. Our contract manufacturing (or private label) sales YTD increased from 37% in 2023 towards 70% in 2024. Leading country supermarkets and international drugstores perform on long duration contracts as to ensure the sustainable sales growth since 2023.

Market

The global demand for oral hygiene products continues to soar, driven by increasing awareness of oral health and hygiene among consumers worldwide. bonyf belongs to the limited number of independent manufacturers for dental effervescent tablets in Europe and MDR certification successfully completed, we enjoy a competitive advantage in terms of market share and positioning.

bonyf uniqueness exist by not only providing the standard omni present formulations but by proposing its own developed healthy, more efficient and performant and patented formulations developed by bonyf own R&D department. “Our goal is to develop a product that not only provides exceptional performance but also promotes overall oral health”.

The unique denture cleansing tablets performance by the formulation named NitrAdine showing the best-in-class disinfection efficiency LOG 5, or disinfecting the denture with 99,999%.

The unique healthy denture fixative cream including its patented formulation replacing mineral oils by olive oil showing the growing recognition of our “Olivafix Gold” brand in the denture fixative creams segment.

bonyf R&D pushing further on the healthiness and uniqueness mission by realizing the new Olivafix Alginate-organic formulation as to become not only best in performance strong hold with 24h* strong hold of the upper dentures, but most healthy denture fixative cream ever formulated. bonyf R&D ensuring future unique products. The growing recognition of our “Olivafix Gold” brand in the denture fixative creams segment further enhances our market presence and customer appeal, with rising inquiries and demand for our patented product.

Sales Forecast

With current negotiations pushing on the contract manufacturing sales part, bonyf is heading to a unprecedent, well balanced and sustainable sales result in 2024.

Conclusion

In summary, the year 2024 promises to be a landmark period for our company, characterized by unparalleled growth and expansion in both sales volume and revenue. Our compliance with the European MDR, coupled with our innovative product offerings and growing market recognition, positions us for sustained success in the years ahead.

With firm orders already in place and increasing demand for our products, we are confident that 2024 will mark a pivotal milestone in our journey towards becoming a dominant force in the global oral hygiene products market.

bonyf’s strengths

• Products with patented formulations
• Produced in Switzerland compliant with stringent international quality regulations
• Proven clinical efficacy
• Commercial presence in 37 countries
• Prospects for solid growth and rapid profitability
• A fast-growing oral and dental care market